Skip to main content

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC

Alice P. Pentland, M.D.

Contact Information

Phone Numbers

Appointment: (585) 275-7546

Administrative: (585) 275-1998

Fax: (585) 273-1346

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Setting



Dr. Pentland, an expert in photobiology and skin cancer, specializes in the treatment of Bullous diseases, such as pemphigus and severe psoriasis. Dr. Pentland has dedicated her career to bringing state-of-the-art technology to support individual health and to creating a rich interdisciplinary environment within the department. She received her undergraduate and medical degrees from the University of Michigan.


Research in the Pentland Lab addresses the role of prostaglandins in skin carcinogenesis and in cell differentiation. The role of these lipid mediators in the induction of squamous cell carcinoma of the skin is being studied in the context of ultraviolet light injury. Recent work has shown that significant contributions to tumor initiation and promotion may be made by eicosanoids (arachidonic acid and its metabolites). Most importantly, non-steroidal anti-inflammatory drugs (NSAIDs), which are inhibitors of prostaglandin synthesis, have been shown to have anti-tumor properties in humans. Unfortunately, NSAIDs chemoprevention is limited by NSAID side effects. However, new data shows the hormone metabolizing enzyme aldo-keto reductase AKR1C3 is also inhibited by most NSAIDs, begging the question whether cyclooxygenase inhibition is actually the key target through which NSAIDs produce their cancer prevention effects. A potential role in cancer for AKR1C3 has been shown in many tumor types. AKR1C3 metabolizes the cyclooxygenase product PGH2 into PGF2alpha, as well as transforming PGD2 into 9alpha11betaPGF2. This activity can shunt prostaglandin metabolism away from pro-differentiation, pro-apoptotic mediators such as PGJ2. AKR1C3 is also the primary enzyme responsible for synthesis of 17Beta-estradiol and testosterone from their respective less active precursors, supporting its role in hormone sensitive tumors. Lastly, AKR1C3 is capable of supporting redox cycling, which can produce mutations that could promote carcinogenesis.

We are testing the hypothesis that AKR1C3 is an important therapeutic target regulating SCC growth, due to PGF2alpha mediated signaling, redox and hormonal metabolic effects on SCC apoptosis, proliferation or invasion. We seek to determine whether this action is distinct from cancer reduction produced by cyclooxygenase. Current work addresses whether AKR1C3 expression is correlated with degree of tumor malignancy, and examines the relative importance of prostanoid metabolism, hormones and oxidative stress in human SCC-derived cell lines. In vivo models are also in use to understand the relative importance of these AKR1C3 activities.



MD | University of Michigan Medical School

Post-doctoral Training & Residency

07/01/1983 - 06/30/1986
Fellowship in Dermatology at Washington University School of Medicine

07/01/1979 - 06/30/1983
Residency in Dermatology at University Of Michigan - Academic Human Resources

07/01/1978 - 06/30/1979
Internship in Internal Medicine at North Carolina Memorial Hospital

VIEW ALL expand_more


2011 - Present
Secretary Treasurer Society for Investigative Dermatology

2011 - 2015
Member NIAMS Council

2010 - 2015
Center for Medical Countermeasures Against Radiation
Sponsor: NIH

2009 - 2011
ACTS Study Section, Member
Sponsor: National Institution of Health

2006 - 2007
Sponsor: Society for Investigative Dermatology

2000 - 2010
PGE2 Receptor Function in Skin
Sponsor: NIH

1999 - 2014
Training Program in Dermatological Research
Sponsor: NIH

Dermatology Award
Sponsor: University of Rochester

VIEW ALL expand_more


Journal Articles

Oleksyn D, Zhao J, Vosoughi A, Zhao JC, Misra R, Pentland AP, Ryan D, Anolik J, Ritchlin C, Looney J, Anandarajah AP, Schwartz G, Calvi LM, Georger M, Mohan C, Sanz I, Chen L. "PKK deficiency in B cells prevents lupus development in Sle lupus mice." Immunology letters.. 2017 May 0; 185:1-11. Epub 2017 Mar 06.

Barlow ML, Cummings RJ, Pentland AP, Love TM, Haidaris CG, Ryan JL, Lord EM, Gerber SA. "Total-Body Irradiation Exacerbates Dissemination of Cutaneous Candida Albicans Infection." Radiation research.. 2016 Nov 0; 186(5):436-446. Epub 2016 Oct 06.

Chen L, Oleksyn D, Pulvino M, Sanz I, Ryan D, Ryan C, Lin CS, Poligone B, Pentland AP, Ritchlin C, Zhao J. "A critical role for the protein kinase PKK in the maintenance of recirculating mature B cells and the development of B1 cells." Immunology letters.. 2016 Apr 0; 172:67-78. Epub 2016 Feb 26.

Books & Chapters

Chapter Title: Photobiology of the Skin
Book Title: Biophotonics
Author List: Pentland AP
Edited By: Pavesi and Fauchet
Published By: Springer-Verlag, Berlin Heidelberg 2008

Chapter Title: Eicosanoids
Book Title: Dermatology in General Medicine
Author List: Pentland, AP
Edited By: Freedberg, Eisen, Wolff, Austen, Goldsmith, Katz
Published By: McGraw-Hill 2003

Chapter Title: Inventing the Future - Tools for Self Health
Book Title: Future of Health Technology
Author List: Pentland, Alice P and Pentland, Alex P
Edited By: R. Bushko
Published By: IOS Press 2002 in Amsterdam